PerpEquities

Equity · Healthcare

Biogen Inc. (BIIB) perpetual futures

BIIB perpetual futures on 4 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade BIIBUSDT.

Biogen Inc. is a biotechnology company developing and commercializing therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.

$251.010.0%NASDAQ closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · BingX (BIIB-USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

4/4 live markets
Venues
4
Live markets
4/4
24h volume
$486.6K
Open interest
$152.9K
Best liquidity
$7.5K
Gate.io
Tightest spread
+29.0 bps
Bybit
Highest volume
$376K
BingX
Settlement mix
USDT · 4/4
Perp/spot vol.
0.00x
Spot volume $265.5M
OI / float
0.00%
Float $36.8B
Spot performance
1D-0.03%
5D-2.53%
1M+13.21%
6M+32.97%
YTD+41.45%
1Y+66.70%

Venue matrix

4 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BingXTradeBIIB-USDTTrading$251.67-21.9% APR
-0.020% every 8h
+29.4 bps$5.3K$376K$99.3USDT-
MEXCTradeBIIB/USDTTrading$249.58-21.9% APR
-0.020% every 8h
+208.7 bps$0$92.1K$135.5KUSDT20x
BybitTradeBIIB/USDTTrading$250.660.0% APR
0.000% every 8h
+29.0 bps$4.8K$12.7K$13.6KUSDT25x
Gate.ioTradeBIIB/USDTTrading$251.010.0% APR
0.000% every 8h
+131.6 bps$7.5K$5.7K$3.6KUSDT20x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 4 venues absorb $10k

Too thin: BingX, Bybit

No fresh book data: Gate.io, MEXC

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

BIIB

Tightest spread

BIIB

Highest volume

BIIB

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-10-28 · next report 2027-02-05 · Updated 82h ago
All financials →

Valuation & key figures

Market cap
$37.5B
Updated 82h ago
Revenue
$10.3B
Trailing 12 months
Revenue growth
+8%
Next fiscal year
Profit margin
+3.4%
P/E
107.5
Peer P/E 29.1
P/S
3.6
Peer P/E
29.1
Similar listed perps
Free cash flow
$2.3B
Trailing 12 months
Net income
$348M
Trailing 12 months
Revenue estimate
$10.6B
Next fiscal year
Earnings
2027-02-05
Revenue est. $2.6B · Updated 82h ago
Dividend
-
Revenue (TTM)$10.3B+3.1% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)7.6%-16.8 pp vs a year agoOperating income $787M
Net income (TTM)$348M-78.4% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$2.34B+2.9% vs a year agoCapex -$95.6M
Diluted EPS (TTM)$2.34-78.7% vs a year agoSum of the last 4 quarters
Net cash-$6.5B-147.1% vs a year agoCash + short-term investments - debt
  • Last report (2026-10-28): revenue beat by 6.4%, EPS beat by 31.7%Revenue $2.8B vs $2.63B expected (+6.4%); EPS $2.62 vs $1.99 (+31.7%).
  • Revenue growth accelerating: 14.2% year on yearQ3 '26 revenue $2.8B, against an average of -0.6% over the four quarters before.
  • Operating margin 7.6% (TTM), -16.8 pp on a year agoOperating income grew -67.8% while revenue grew 3.1%.
  • 171.3% of pre-tax profit is eaten by non-operating lossesPre-tax income $290M vs operating income $787M (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.

Revenue, operating income and growth

quarterly

Revenue by business line

latest quarter
LineRevenuey/yShare
MS Product Revenues$919M-13.4%40.0%
TYSABRI product$437M+1.2%19.0%
SPINRAZA$461M+23.2%20.0%
Fumarate$274M-28.4%11.9%
Interferon$208M-15.7%9.1%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 323 lines Biogen Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-05
Revenue est. $2.6B · Updated 82h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 202612.47$10.6B+8%19
FY 202716.27$10.8B+10%20
FY 202818.34$11.1B+13%11
FY 202920.38$11.4B+17%4
FY 203021.08$11.7B+19%4
Q1 20273.55$2.6B+5%8

Company events

6
2027-02-05EarningsActual - / Estimate 2.86-
2026-10-28Earnings · Before market openActual 2.62 / Estimate 1.99Beat
2026-07-29EarningsActual 3.6 / Estimate 2.94Beat
2026-04-29EarningsActual 3.57 / Estimate 3.05Beat
2026-02-06EarningsActual 1.99 / Estimate 1.63Beat
2025-10-30EarningsActual 4.81 / Estimate 3.88Beat

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Oct 11, 2026, 10:43 PM UTC

Company profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Christopher A. Viehbacher
Employees
7,500
IPO date
Sep 17, 1991
Country
US
Exchange
NASDAQ Global Select
Website
Altman Z-scorei2.91
Piotroski scorei4/9
Overall ratingiB+
Owner earningsi$519.39M$3.49 per share
ESG risk ratingiB+Industry rank: 8 out of 28

Rating factors

Return on equityi
3
Return on assetsi
4
Debt to equityi
2
Price to earningsi
1
Price to booki
3
Market cap history
$32.36B+10.1%Jun 26 – Sep 26
$29.40B$30.88B$32.36BLow: $29.40B · 2026-06-22Latest: $32.36B · 2026-09-21Jun 26Jul 26Aug 26Sep 26
Latest: $32.36B · 2026-09-21High: $32.36B · 2026-09-21Low: $29.40B · 2026-06-22
Largest fund holders
FundWeightShares held
VPMAX1.88%8.4M
VTI0.04%4.7M
FCNKX0.59%4.7M
VOO0.05%3.9M
VCPA.S0.07%3.6M
VO0.3%3.2M
VHCAX1.72%2.6M
VGHAX1.4%2.5M
IVV0.05%1.9M
FXAIX0.05%1.8M
1557.T0.05%1.8M
SPY0.05%1.8M

Analyst track record

How the analysts covering BIIB have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings254695
Analysts3745
Buy / hold / sell139 / 110 / 5405 / 285 / 5
Upgrades / downgrades / initiations9 / 2 / 310 / 12 / 10
Price targets hit / missed175 / 50 (78%)367 / 235 (61%)
Avg. return after a rating (TipRanks)+16.5%+16.5%
Best / worst call+84.9% / -23.2%+117.1% / -37.6%

After buy calls on this stock: median 21-day move +0.6% vs S&P 500 -1.8% (n = 404)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Salveen RichterGoldman Sachs54% hit rate on this stock · 13 targets measuredBuytarget $250Jul 13, 2026
  2. Andrew FeinH.C. Wainwright42% hit rate on this stock · 12 targets measuredBuytarget $251Jul 30, 2026
  3. Phil NadeauTD Cowen41% hit rate on this stock · 17 targets measuredBuytarget $250Oct 28, 2026

Latest ratings

DateAnalystCallTarget
Nov 2, 2026Evan SeigermanBMO CapitalHoldMaintained$250
Nov 2, 2026Ananda GhoshH.C. WainwrightBuyReiterated$270
Nov 2, 2026Yatin SunejaGuggenheimBuyMaintained$300
Oct 29, 2026Danielle BrillTruist FinancialBuyMaintained$260
Oct 29, 2026Paul MatteisStifel NicolausBuyMaintained$286
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$180$200$220$240$260Dec 25 · Buy 14 · Hold 14 · Sell 1Dec 25Jan 26 · Buy 12 · Hold 15 · Sell 1Feb 26 · Buy 13 · Hold 16 · Sell 1Feb 26Mar 26 · Buy 13 · Hold 16 · Sell 1Apr 26 · Buy 14 · Hold 13 · Sell 1Apr 26May 26 · Buy 16 · Hold 12 · Sell 1Jun 26 · Buy 18 · Hold 11 · Sell 1Jun 26Jul 26 · Buy 20 · Hold 10 · Sell 1Aug 26 · Buy 21 · Hold 9 · Sell 1Aug 26Sep 26 · Buy 22 · Hold 9 · Sell 1Oct 26 · Buy 27 · Hold 7 · Sell 1Oct 26Nov 26 · Buy 27 · Hold 7 · Sell 1Dec 25 · avg. target $178Jan 26 · avg. target $188Feb 26 · avg. target $206Mar 26 · avg. target $207Apr 26 · avg. target $211May 26 · avg. target $219Jun 26 · avg. target $220Jul 26 · avg. target $230Aug 26 · avg. target $237Sep 26 · avg. target $240Oct 26 · avg. target $261Nov 26 · avg. target $261Dec 25 · month-end close $176Jan 26 · month-end close $180Feb 26 · month-end close $192Mar 26 · month-end close $183Apr 26 · month-end close $189May 26 · month-end close $196Jun 26 · month-end close $216Jul 26 · month-end close $203Aug 26 · month-end close $217Sep 26 · month-end close $226Oct 26 · month-end close $254Nov 26 · month-end close $254

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 2, 2026 · 254 ratings

Frequently asked questions

Where can I trade BIIB perpetual futures?

Biogen Inc. (BIIB) perpetual futures trade on 4 crypto venues, including BingX, MEXC, Bybit. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade BIIB around the clock?

Yes. Unlike the underlying stock, BIIB perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on BIIB perpetuals?

Right now the BIIB perp funding rate is -11.0% annualized (venue median), ranging from -21.9% to 0.0% across 4 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the BIIB perp price compare to the Biogen Inc. stock?

The venue-median BIIB perp mark is $250.8 versus a reference stock price of $251, a basis of -0.1%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a BIIB perpetual future?

A BIIB perpetual is a derivative that tracks the price of Biogen Inc. with no expiry date. It lets you take long or short exposure to Biogen Inc. on crypto venues, around the clock.

What is BIIBUSDT perpetual?

BIIBUSDT is the symbol most crypto exchanges use for the Biogen Inc. perpetual settled in USDT (Tether). It tracks the BIIB share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

BIIB perpetuals · perpequities.comBIIB perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/biib-perp"><img src="https://perpequities.com/badge/biib-perp.svg" width="240" height="64" alt="BIIB perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of BIIB perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for BIIB — one email every Sunday.

Watchlist and alerts

Price and funding alerts for BIIB, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X